DIEGO
FERNANDEZ LAZARO
PROFESOR CONTRATADO DOCTOR
Universidad de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Salamanca (12)
2023
2022
-
25-Hydroxyvitamin D Serum Levels Linked to Single Nucleotide Polymorphisms (SNPs) (rs2228570, rs2282679, rs10741657) in Skeletal Muscle Aging in Institutionalized Elderly Men Not Supplemented with Vitamin D
International Journal of Molecular Sciences, Vol. 23, Núm. 19
2021
-
Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2
Frontiers in Immunology, Vol. 12
-
Long COVID a new derivative in the chaos of SARS-CoV-2 infection: The emergent pandemic?
Journal of Clinical Medicine, Vol. 10, Núm. 24
2020
-
Clinical perspective and translational oncology of liquid biopsy
Diagnostics, Vol. 10, Núm. 7
-
Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers
Diagnostics, Vol. 10, Núm. 4
2019
-
Adherence to treatment and related factors among patients with chronic conditions in primary care: A cross-sectional study
BMC Family Practice, Vol. 20, Núm. 1
-
Medication adherence and barriers among low-income, uninsured patients with multiple chronic conditions
Research in Social and Administrative Pharmacy, Vol. 15, Núm. 6, pp. 744-753
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2012
-
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
Annals of Hematology, Vol. 91, Núm. 2, pp. 257-269
2011
-
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
Haematologica, Vol. 96, Núm. 5, pp. 687-695
2010
-
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Haematologica, Vol. 95, Núm. 5, pp. 794-803